Using Real World Data to Individualize HCV Management

Volume 5, Issue 10.

In this podcast Dr. David Wyles discusses managing DAA failures with the newly approved treatment options for hepatitis C.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

HBV: Addressing Current Gaps in Diagnosis and Linkage to Care

Volume 5, Issue 2.

Our guests authors are Mindie Nguyen, MD, MAS, from Associate Professor of Medicine at Stanford University, and Dr. Iris Liou, MD of the University of Washington.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

Extrahepatic Manifestations of Hepatitis C: Screening and Management

Volume 4, Issue 14.

Drs Jordan Feld, MD, MPH and Joel Emery, HBSc, MD cover the important topic of Extrahepatic Manifestations of Hepatitis C: Screening and Management in the format of case-study scenarios for the clinical practice.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

Sofosbuvir/Velpatasvir fixed dose combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study

Volume 4, Issue 8, Part 3.

Raymond T. Chung, MD from Harvard Medical School interviews Dr. David Wyles from the University of California San Diego about his presentation: Sofosbuvir/Velpatasivr Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study, presented at the April 2016 EASL meeting.

Resistance Analysis for Ledipasvir/Sofosbuvir containing regimens in patients infected with chronic HCV who have advanced liver disease or are post Liver Transplant (SOLAR-1 and 2 STUDIES)

Volume 4, Issue 8, Part 2.

Raymond T. Chung, MD from Harvard Medical School interviews Dr. Michael Charlton from Intermountain Medical Center about his abstract: Resistance Analyses for Ledipasvir/Sofosbuvir-Containing Regimens in Patients Infected with Chronic HCV Who Have Advanced Liver Disease or are Post Liver Transplant(SOLAR-1 & 2 Studies), presented at the April 2016 EASL meeting.

High Efficacy of Sofosbuvir/Velpatasvir plus GS-9857 for 12 Weeks in Treatment-experienced Genotype 1-6 HCV-Infected Patients, Including those Previously Treated with Direct-acting Antivirals

Volume 4, Issue 8, Part 1.

Raymond T. Chung, MD from Harvard Medical School interviews Dr. Eric Lawitz from the University of Texas Health Science Center about his presentation: High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals presented at the April 2016 EASL meeting.

Hepatitis C Treatment in the HIV Coinfected and Dialysis Populations

Volume 4, Issue 7.

Drs Paul Martin, MD and Kalyan Ram Bhamidimarri, MD cover the important topic of Hepatitis C Treatment in the HIV Coinfected and Dialysis Populations in the format of case-study scenarios for the clinical practice.

Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015

Volume 4, Issue 3, Part 3.

Mark S. Sulkowski from the Johns Hopkins University School of Medicine interviews Dr. Gregory Dore from the Kirby Institute, UNSW Australia about the C-EDGE CO-STAR study.

Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015

Volume 4, Issue 3, Part 2.

Mark S. Sulkowski from the Johns Hopkins University School of Medicine interviews Dr. Graham Foster from Queen Mary University of London about the ASTRAL-3 study.